Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Merck & Co. patents NPR1 agonists

Dec. 16, 2020

Mesoblast reports topline phase III data on Revascor in advanced chronic heart failure

Dec. 15, 2020

Regenerative approach shows promise in pediatric heart disease

Dec. 14, 2020

Cytokinetics advances phase II trial of CK-3773274 for symptomatic obstructive HCM

Dec. 10, 2020

DMC issues recommendation regarding global phase III study of PLX-PAD in CLI

Dec. 10, 2020

New Na(+)/H(+) exchanger 3 inhibitors identified at Lilly

Dec. 10, 2020

FDA issues complete response letter for Furoscix

Dec. 9, 2020

AstraZeneca initiates first-in-human phase I study of AZD-3427

Dec. 7, 2020

Researchers develop a feline model of heart failure with preserved eject fraction

Dec. 4, 2020

CV outcomes from FIDELIO-DKD trial of finerenone in patients with CKD and T2D

Dec. 4, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...